<qa>  What is a Phase II multicentre, double-blinded, vehicle-controlledThis is a Phase II multi-centre, double-blinded, vehicle-controlled, repeated and multiple dose, study to evaluate dose response, safety, tolerability and efficacy of 2.5 and 5 cis-UCA compared to placebo, and investigator-blinded to compare the safety, tolerability and efficacy of cis-UCA to the active comparator Protopic 0.1 in patients with moderate or severe chronic atopic dermatitis treated for up to 28 days. 